PBYI

3.56

0.84% -0.03

Handel nachbörslich: 3.56

Puma Biotechnology Inc (PBYI)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.59

Offen:

$3.58

24-Stunden-Volumen:

244.22K

Relative Volume:

0.70

Marktkapitalisierung:

$178.70M

Einnahmen:

$230.47M

Nettoeinkommen (Verlust:

$30.28M

KGV:

5.8361

EPS:

0.61

Netto-Cashflow:

$38.86M

1W Leistung:

+7.55%

1M Leistung:

+8.37%

6M Leistung:

+14.10%

1J Leistung:

+14.84%

1-Tages-Spanne:

$3.545

$3.64

1-Wochen-Bereich:

$3.26

$3.65

52-Wochen-Spanne:

$2.225

$4.13

Puma Biotechnology Inc Stock (PBYI) Company Profile

Firmenname

Puma Biotechnology Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

(424) 248-6500

Adresse

10880 WILSHIRE BLVD., LOS ANGELES, CA

Mitarbeiter

172

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PBYI's Discussions on Twitter

Vergleichen Sie PBYI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PBYI Puma Biotechnology Inc	3.56	178.70M	230.47M	30.28M	38.86M	0.61
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-09-28	Hochstufung	Citigroup	Neutral → Buy
2020-06-25	Fortgesetzt	BofA/Merrill	Underperform
2019-10-08	Herabstufung	Goldman	Neutral → Sell
2019-05-10	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2019-05-10	Herabstufung	Citigroup	Buy → Neutral
2019-01-17	Eingeleitet	Leerink Partners	Mkt Perform
2019-01-03	Herabstufung	Guggenheim	Buy → Neutral
2018-11-19	Hochstufung	Goldman	Sell → Neutral
2018-11-02	Herabstufung	BofA/Merrill	Buy → Underperform
2018-11-02	Herabstufung	JP Morgan	Neutral → Underweight
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-09-17	Eingeleitet	Goldman	Sell
2018-05-11	Bestätigt	Stifel	Buy
2017-11-10	Bestätigt	Citigroup	Buy
2017-11-10	Bestätigt	RBC Capital Mkts	Sector Perform
2017-10-02	Bestätigt	Stifel	Buy
2017-09-11	Bestätigt	Credit Suisse	Outperform
2017-07-10	Fortgesetzt	Leerink Partners	Outperform
2017-06-06	Bestätigt	RBC Capital Mkts	Sector Perform
2017-05-25	Bestätigt	RBC Capital Mkts	Sector Perform
2017-03-02	Bestätigt	RBC Capital Mkts	Sector Perform

Alle ansehen

Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten

Jun 13, 2025

Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks

Jun 13, 2025

Jun 11, 2025

Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance

Jun 11, 2025

Jun 10, 2025

With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance

Jun 10, 2025

Jun 08, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 08, 2025

Jun 06, 2025

78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World

Jun 06, 2025

Jun 05, 2025

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 - BioSpace

Jun 05, 2025

Jun 04, 2025

Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan

Jun 04, 2025

May 28, 2025

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise

May 28, 2025

May 26, 2025

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance

May 26, 2025

May 20, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st

May 20, 2025

May 17, 2025

Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

May 17, 2025